- Nanoparticle-based Olaparib delivery enhances its effect, and improves drug sensitivity to cisplatin in triple negative breast cancer
Shentao Zhang et al, 2022, Journal of Drug Delivery Science and Technology CrossRef - Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
Inken Flörkemeier et al, 2022, International Journal of Molecular Sciences CrossRef - Cisplatin for cancer therapy and overcoming chemoresistance
Ranmali Ranasinghe et al, 2022, Heliyon CrossRef - Analysis of olaparib efficacy in patients with serous ovarian cancer
null null et al, 2023, Hirurg (Surgeon) CrossRef - Hybrid nano-architectures loaded with metal complexes for the co-chemotherapy of head and neck carcinomas
Melissa Santi et al, 2023, Journal of Materials Chemistry B CrossRef - PARP deficiency causes hypersensitivity to Taxol through oxidative stress induced DNA damage
Junko Maeda et al, 2023, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis CrossRef - Triple Combinations of Histone Lysine Demethylase Inhibitors with PARP1 Inhibitor–Olaparib and Cisplatin Lead to Enhanced Cytotoxic Effects in Head and Neck Cancer Cells
Dawid Dorna et al, 2024, Biomedicines CrossRef - PROSPECTS FOR THE USE OF PLATINUM DRUGS
Sadkova Yu.A. et al, 2023, "Medical & pharmaceutical journal "Pulse" CrossRef - Circ_0002722-induced regulation of YAP promotes platinum resistance in oral squamous cell carcinoma: Implications for verteporfin therapy
Hsiao-Chi Tsai et al, 2024, Biochemical Pharmacology CrossRef - The Conjugates of Indolo[2,3-b]quinoline as Anti-Pancreatic Cancer Agents: Design, Synthesis, Molecular Docking and Biological Evaluations
Marcin Cybulski et al, 2024, International Journal of Molecular Sciences CrossRef